2020 American Society of Hematology Virtual Annual Meeting*

Download All
December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Expert faculty review and share their insights and perspectives on key findings in multiple myeloma presented at the 2020 ASH Annual Meeting.
Shaji K. Kumar, MD
Sagar Lonial, MD

Multiple Myeloma

Slidesets First-in-Human Phase I UNIVERSAL Trial of Allogeneic CAR T-Cell Therapy With ALLO-715 (Anti-BCMA) and ALLO-647 (Anti-CD52) in Patients With R/R MM
Slidesets Updated Analysis of Phase I CRB-402: bb21217 Anti-BCMA CAR T-Cell Therapy in Patients With R/R MM
Slidesets PRIME Phase I/II Trial of P-BCMA-101: Novel CAR T-Cell Therapy in R/R Multiple Myeloma
Slidesets Phase II DREAMM-2 Study of Belantamab Mafodotin in R/R MM: Outcomes by Number of Prior Therapies
Slidesets Phase II DREAMM-6 Arm B: Preliminary Analysis of Belantamab Mafodotin + Bortezomib/Dexamethasone in R/R MM
Slidesets DREAMM-2: Ocular Safety During Phase II Study of Belantamab Mafodotin in R/R MM
Slidesets CARTITUDE-1 Phase Ib/II Study of Ciltacabtagene Autoleucel: BCMA-Directed CAR T-Cell Therapy in Patients With R/R MM
Slidesets BCMA-Targeted ADC MEDI2228: First-in-Human Phase I Study in Patients With R/R Multiple Myeloma
Slidesets Phase I Trial: Updated Analysis of BCMA x CD3 Bispecific Antibody Teclistamab (JNJ-64007957) in Patients With R/R MM
Slidesets First-in-Human Phase I Study of AMG 701: Anti-BCMA Bispecific Antibody in Patients With R/R MM
Slidesets MAIA Updated Analysis: Phase III Study of D-Rd vs Rd for ASCT-Ineligible Newly Diagnosed MM
Slidesets First-in-Human Phase I Trial of GPCR5D x CD3 Bispecific Antibody Talquetamab in Patients With R/R MM
Slidesets First-in-Human Phase I Study of BCMA x CD3 Bispecific Antibody REGN5458 in Patients With R/R MM
Slidesets Cevostamab: Novel FcRH5 x CD3 Bispecific Antibody in Patients With R/R MM
Slidesets Phase III APOLLO: Daratumumab SC + Pom/Dex vs Pom/Dex Alone in Patients With R/R MM
Slidesets GRIFFIN Maintenance Phase Update: Daratumumab + VRd → Dara-R vs VRd → R Alone for ASCT-Eligible Patients With Newly Diagnosed MM
Slidesets TOURMALINE-MM2: Oral Ixazomib-Rd vs Placebo-Rd for ASCT-Ineligible Patients With Newly Diagnosed MM
Slidesets Phase I/II Trial of Iberdomide Plus Daratumumab/Dex or Bortezomib/Dex in R/R MM
Slidesets ALGONQUIN Part 1: Phase I Trial of Belantamab Mafodotin With Pomalidomide/Dexamethasone in Patients With R/R Multiple Myeloma
Slidesets STOMP Phase I/II Trial: Selinexor/Pomalidomide/Dexamethasone in R/R MM After ≥ 2 Previous Therapies

Expert faculty review and share their insights and perspectives on key findings in multiple myeloma from ASH 2020.

Shaji K. Kumar, MD Sagar Lonial, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits™ Released: March 22, 2021 Expired: March 21, 2022

In this commentary, 2 experts discuss their top presentation choices at ASH 2020 in myeloma with the most potential to impact clinical practice.

Shaji K. Kumar, MD Sagar Lonial, MD Released: March 8, 2021

Two experts discuss results from key studies in multiple myeloma from the virtual Hematology 2020 meeting, including updated data on treatment options for newly diagnosed disease and an analysis of available agents for relapsed/refractory myeloma.

Shaji K. Kumar, MD Sagar Lonial, MD Released: March 12, 2021
Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue